Surmodics announces agreement with Genentech/Roche to combine proprietary drug delivery system with Lucentis (ranibizumab) for the treatment of wet macular degeneration.
Lucentis is the second anti-VEGF drug FDA approved for the treatment of wet macular degeneration. It is an effective treatment for wet macular degeneration. The formulation differs from Macugen and Avastin as do the visual results.